Skip to content Skip to navigation

Continuing Education Quiz

February 1, 2011
by root
| Reprints

Earn continuing education credits by taking this quiz on the article that begins on page 30 of this issue. A grade of 70% or above will earn you a certificate of completion for two nationally certified continuing education hours. This is an open-book quiz. After reading the article, complete the quiz by circling one of the three multiple-choice answers for each question. Please give only one response per question. Incomplete answers will be marked as incorrect. Send a photocopy of the page along with your payment of $35 (NAADAC members) or $50 (nonmembers). Please complete fully the information section below; print clearly.

Data demonstrate buprenorphine's effectiveness

1. One of the two commonly used formulations of buprenorphine combines buprenorphine and:

a. Naltrexone.

b. Naloxone.

c. Methadone.

2. The authors consider expansion of this a necessary factor in narrowing the opioid dependence treatment gap.

a. Office-based treatment

b. Public funding

c. Treatment that excludes pharmacology

3. The authors state that buprenorphine maintenance is not buprenorphine addiction because clients do not experience:

a. Physical dependence.

b. Withdrawal with abrupt cessation.

c. Compulsive, uncontrolled use.

4. The authors point to research showing this level of treatment retention with buprenorphine at the six-month mark.

a. 20 to 30%

b. 35 to 40%

c. 50 to 60%

5. A recent trial of buprenorphine detoxification approaches found this percentage of active use of illicit opioids among subjects after a taper.

a. 55%

b. 70%

c. 85%

6. The authors cite a study of long-term buprenorphine maintenance that found this percentage of opioid-positive drug tests during years 2 to 5 of follow-up.

a. 9%

b. 21%

c. 33%

7. The patients in the study that is referenced in quiz question 6 received this along with their medication.

a. Cognitive-behavioral therapy

b. Brief physician counseling

c. Antidepressants

8. The authors consider buprenorphine to be:

a. A miracle cure for opioid dependence.

b. Sufficient without other interventions.

c. A vehicle for stabilization to allow the client to engage in rehabilitation.

9. The authors cite the problem of “script docs” who interact with patients during:

a. Phone appointments.

b. 5- to 10-minute refill visits.

c. Half-hour sessions.

10. The authors express concerns about “prescriptive detoxification” in office-based treatment that generally involves a taper of this duration.

a. 1 week

b. 4 weeks

c. 10 weeks

Addiction Professional 2011 January-February;9(1):37